

Resource Summary Report

Generated by [NIF](#) on Jul 28, 2026

Mouse Anti-p14 ARF Monoclonal Antibody, Unconjugated, Clone 4C6/4

RRID:AB_490785

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2407, RRID:AB_490785

Antibody Information

URL: http://antibodyregistry.org/AB_490785

Proper Citation: Cell Signaling Technology Cat# 2407, RRID:AB_490785

Target Antigen: p14 ARF

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: W, IHC-P. Consolidation on 11/2018: AB_10692666, AB_490785.

Antibody Name: Mouse Anti-p14 ARF Monoclonal Antibody, Unconjugated, Clone 4C6/4

Description: This monoclonal targets p14 ARF

Target Organism: human

Clone ID: Clone 4C6/4

Antibody ID: AB_490785

Vendor: Cell Signaling Technology

Catalog Number: 2407

Record Creation Time: 20250820T011050+0000

Record Last Update: 20250820T101435+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-p14 ARF Monoclonal Antibody, Unconjugated, Clone 4C6/4.

No alerts have been found for Mouse Anti-p14 ARF Monoclonal Antibody, Unconjugated, Clone 4C6/4.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Lan Y, et al. (2025) Synonymous mutations promote tumorigenesis by disrupting m6A-dependent mRNA metabolism. *Cell*, 188(7), 1828.

Minami JK, et al. (2023) CDKN2A deletion remodels lipid metabolism to prime glioblastoma for ferroptosis. *Cancer cell*, 41(6), 1048.

Kuganesan N, et al. (2021) Tumor suppressor p53 promotes ferroptosis in oxidative stress conditions independent of modulation of ferroptosis by p21, CDKs, RB, and E2F. *The Journal of biological chemistry*, 297(6), 101365.

Tan Y, et al. (2021) Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 27(4), 1200.

Zeng H, et al. (2018) Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation. *Cancer cell*, 34(1), 56.